Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11275957 | 0.89 | PTGDR2 (0.61) | ALDH1A1MAPTKDM4EPTGDR2GAA | |
| SCHEMBL7050538 | 0.86 | MAPT (0.59) | ALDH1A1MAPTKDM4EPTGDR2GAA | |
| SCHEMBL7054803 | 0.86 | ALDH1A1 (0.54) | ALDH1A1MAPTKDM4EPTGDR2GAA | |
| SCHEMBL11455410 | 0.81 | PTGS2 (0.66) | ALDH1A1MAPTKDM4EPTGDR2GAA | |
| SCHEMBL11563601 | 0.77 | ALDH1A1 (0.72) | ALDH1A1MAPTKDM4EGAALMNA | |
| SCHEMBL10799962 | 0.76 | ALDH1A1 (0.61) | ALDH1A1MAPTKDM4EGAALMNA | |
| SCHEMBL10799967 | 0.76 | ALDH1A1 (0.61) | ALDH1A1MAPTKDM4EGAALMNA | |
| SCHEMBL5530041 | 0.76 | ALDH1A1 (0.61) | ALDH1A1MAPTKDM4EGAALMNA | |
| SCHEMBL8067414 | 0.76 | MAPT (0.69) | ALDH1A1MAPTKDM4EGAALMNA | |
| SCHEMBL11274476 | 0.75 | ALOX5 (0.73) | ALDH1A1MAPTKDM4EPTGDR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602895-B2 | Inhibitors of factor Xa with a neutral P1 specificity group | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20030092740-A1 | Inhibitors of factor Xa with a neutral P1 specificity group | GALEMMO ROBERT A (US) | 2003-05-15 | — | — | US | disclosed |
| US-6403620-B1 | ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-11 | — | — | US | disclosed |
| EP-0991625-A2 | INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 2000-04-12 | — | — | EP | disclosed |
| US-5998424-A | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1998057937-A2 | INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092740-A1 | Inhibitors of factor Xa with a neutral P1 specificity group | F12, F11, SERPINC1 | ALDH1A1 1329/4885MAPT 4818/4885KDM4E 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.